Unknown Analyst

Bobby Hill, Senior Vice President and CCO; and then finally, Luke Power, CFO from Caris. They recently IPO-ed less than a year ago, and we'll have a presentation. If you have any questions towards the last 2 minutes, please raise your hand. We'll be happy to take them. Thank you for being here.

Unknown Executive

Great. Well, thank you. This is our first conference here actually after many being public with our IPO last June. So it's a pleasure to be here. And I think my main point that I'd like to just start out with is although we've been at this since 2008 with our company, we're looking at opportunities in the marketplace that we think are more remarkable facing our platform than we've ever seen.

We've been building this business since 2008. We got a very early look at multiomics with the Molecular Profile Institute. We launched, as you know, Whole Exome, Whole Transcriptome, 23,000 genes well in advance of anybody in the marketplace, and that has really helped define us and has put us in a position here to benefit, we think, from all of these amazing trends in precision medicine, precision oncology and in particular, cancer genomics.

We've been building this platform for many years. We think it's defined in large part by our technology the 23,000 genes is not a reflex or part of the menu, but every single patient has gotten this for many, many years. So we're scaled up now. We're annualizing at over 200,000 profiles on